The global blood-based biomarker for Alzheimer’s disease market is emerging as a transformative segment within the broader neurodiagnostics and precision medicine landscape. Alzheimer’s disease, a progressive neurodegenerative disorder, continues to impose a significant clinical, social, and economic burden worldwide. Traditional diagnostic approaches relying on cerebrospinal fluid (CSF) analysis and neuroimaging are often invasive, expensive, and limited in accessibility. In contrast, blood-based biomarkers offer a minimally invasive, scalable, and cost-effective alternative, enabling earlier detection, improved patient stratification, and better monitoring of disease progression. As healthcare systems increasingly emphasize early diagnosis and personalized treatment pathways, blood-based biomarker technologies are gaining rapid acceptance across clinical and research settings.
Access key findings
and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86889
Market Size and Growth
In 2024, the global blood-based biomarker for Alzheimer’s disease market was
valued at US$ 127.4 Mn. Supported by robust research pipelines, rising
diagnostic demand, and technological innovation, the market is projected to
reach US$ 554.2 Mn by 2035. This expansion represents a strong compound annual
growth rate (CAGR) of 14.3% from 2025 to 2035. The sustained growth trajectory
reflects increasing investments in biomarker validation, regulatory progress
toward clinical adoption, and the growing role of blood-based tests in
large-scale population screening and pharmaceutical trials.
Market Segmentation
The market can be segmented based on biomarker type, technology platform, end
user, and application. By biomarker type, key segments include amyloid beta,
phosphorylated tau (p-tau), neurofilament light chain (NfL), and other emerging
biomarkers that reflect neurodegeneration and synaptic dysfunction. Technology
segmentation encompasses immunoassays, mass spectrometry, and next-generation
ultra-sensitive platforms that allow detection of low-abundance proteins in
blood. End users range from hospitals and diagnostic laboratories to research
institutes and pharmaceutical companies, with applications spanning early
diagnosis, disease monitoring, drug development, and clinical trial enrichment.
Regional Analysis
Geographically, North America dominates the global market, driven by advanced
healthcare infrastructure, strong research funding, and early adoption of novel
diagnostic technologies. The United States, in particular, benefits from a high
prevalence of Alzheimer’s disease and an active biotechnology ecosystem. Europe
represents another significant market, supported by government-backed dementia
initiatives and collaborative research programs. Meanwhile, Asia Pacific is
expected to witness the fastest growth over the forecast period, fueled by
rising awareness, expanding geriatric populations, and increasing investments
in diagnostic innovation across countries such as China, Japan, and South
Korea.
Competitive Landscape
The global blood-based biomarker for Alzheimer’s disease market is moderately
competitive, with a mix of established diagnostics leaders and innovative
biotechnology firms. Key players include Biogen Inc., Beckman Coulter, Inc.
(Danaher Corporation), Fujirebio, C2N Diagnostics, F. Hoffmann-La Roche Ltd,
Quest Diagnostics, ALZpath Inc., Diagnostic BioSystems Inc., Quanterix, Novus
Biologicals, Sysmex Corporation, Shimadzu Corporation, Alamar Biosciences,
Inc., BGI Genomics, and Diadem srl. These companies are actively investing in
research and development, strategic collaborations, and product
commercialization to strengthen their market positions.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware,
United States, provides custom research and consulting services. Our exclusive
blend of quantitative forecasting and trends analysis provides forward-looking
insights for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and various tools
& techniques to gather and analyses information.
Our data
repository is continuously updated and revised by a team of research experts,
so that it always reflects the latest trends and information. With a broad
research and analysis capability, Transparency Market Research employs rigorous
primary and secondary research techniques in developing distinctive data sets
and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE
HEADQUARTER DOWNTOWN,
1000 N.
West Street,
Suite 1200,
Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453